EKI1 Antibody

What is the EKI1 antibody and what protein does it target?

The EKI1 antibody is a purified rabbit polyclonal antibody specifically designed to target the ethanolamine kinase 1 protein (ETNK1). This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide corresponding to amino acids 1-30 from the N-terminal region of human Ethanolamine Kinase (EKI1). The antibody recognizes the ETNK1 protein, which functions in the first committed step of the phosphatidylethanolamine synthesis pathway .

ETNK1 (Ethanolamine Kinase 1) is a cytosolic enzyme that catalyzes the phosphorylation of ethanolamine, a critical step in phosphatidylethanolamine biosynthesis. It exhibits high specificity for ethanolamine and shows negligible kinase activity on choline. This enzyme may represent a rate-controlling step in the phosphatidylethanolamine biosynthetic pathway .

What are the known specificities and cross-reactivities of EKI1 antibodies?

EKI1 antibodies, particularly the N-terminal targeting polyclonal antibody, have demonstrated reactivity to both human and mouse ETNK1 proteins. The antibody specifically recognizes the target sequence within the N-terminal region (amino acids 1-30) of the ETNK1 protein. This specificity is crucial for research applications requiring precise detection of ETNK1 without cross-reactivity to other related proteins .

When selecting an EKI1 antibody for experiments, researchers should note that antibody specificity is a critical consideration. Similar to validation processes used for other antibodies like the EP1 rabbit monoclonal antibody (although for a different target), comprehensive validation of EKI1 antibodies should include testing across multiple tissue types where ETNK1 is known to be expressed, such as kidney, liver, placenta, heart, leukocytes, ovary, and testis .

What are the recommended storage and handling procedures for EKI1 antibodies?

For optimal maintenance of EKI1 antibody activity and specificity, the following storage and handling guidelines should be followed:

• Short-term storage (up to 2 weeks): Maintain refrigerated at 2-8°C

• Long-term storage: Store at -20°C in small aliquots to prevent freeze-thaw cycles

• Buffer composition: The antibody is typically supplied in PBS with 0.09% (W/V) sodium azide

• Preparation method: The antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS

These storage conditions are crucial for maintaining antibody performance, as repeated freeze-thaw cycles can degrade antibody quality and affect experimental outcomes.

How should experimental controls be designed for validating EKI1 antibody specificity?

Designing appropriate controls is essential for validating EKI1 antibody specificity. Following established best practices for antibody validation:

Positive Controls:

• Use tissues or cell lines with known high expression of ETNK1 such as kidney, liver, or placenta tissues

• Consider using recombinant ETNK1 protein as a standard

• Overexpression systems where ETNK1 has been transfected can serve as strong positive controls

Negative Controls:

• Tissues or cell lines with confirmed absence of ETNK1 expression

• Pre-absorption of the antibody with the immunizing peptide

• Primary antibody omission controls

• Secondary antibody-only controls to assess non-specific binding

Additional Validation Approaches:

• Knockdown validation: Compare staining in ETNK1 siRNA/shRNA treated cells vs. controls

• Competing peptide: Pre-incubation of the antibody with excess immunizing peptide

• Multiple antibodies: Use of independent antibodies targeting different epitopes of ETNK1

The interpretation of control results should follow this framework:

This systematic approach to controls ensures that experimental findings are reliable and reproducible, which is critical for advancing research on ETNK1 .

What methodological considerations should be addressed when using EKI1 antibody for Western blot analysis?

When employing EKI1 antibodies for Western blot analysis, researchers should consider the following methodological aspects:

• Sample Preparation:

  • Prepare cell or tissue lysates using appropriate lysis buffers containing protease inhibitors

  • Determine protein concentration using Bradford or BCA assays to ensure equal loading

  • Denature proteins with SDS and reducing agents at 95-100°C for 5 minutes

• Electrophoresis and Transfer Parameters:

  • Use appropriate percentage acrylamide gels based on the size of ETNK1 (calculated MW: 50,968 Da)

  • Ensure efficient protein transfer to PVDF or nitrocellulose membranes

  • Verify transfer efficiency with reversible protein stains

• Antibody Incubation:

  • Block membranes with 5% non-fat milk or BSA in TBST

  • Use recommended dilution for EKI1 antibody (1:1000 for Western blot)

  • Incubate at 4°C overnight for optimal binding

• Detection and Analysis:

  • Use appropriate HRP-conjugated secondary antibodies

  • Apply ECL substrate for visualization

  • Analyze band intensity using densitometry software for quantitative assessment

• Troubleshooting Common Issues:

  • High background: Increase blocking time or stringency of wash steps

  • Absence of signal: Check protein loading, transfer efficiency, and antibody dilution

  • Multiple bands: Evaluate potential isoforms, degradation products, or non-specific binding

When analyzing results, researchers should compare the observed molecular weight with the calculated molecular weight of ETNK1 (50,968 Da) to confirm specificity .

How do concordance rates between different antibodies targeting the same protein inform EKI1 antibody selection?

Concordance analysis between different antibodies targeting the same protein provides valuable insights for antibody selection. Drawing from studies with other antibodies, such as the EP1 and SP1 antibodies for estrogen receptor:

As illustrated in other antibody validation studies, comparative analysis frameworks similar to this table can be applied to evaluate EKI1 antibodies:

This systematic evaluation helps ensure selection of the most appropriate antibody for specific experimental contexts .

What protocols are recommended for optimizing EKI1 antibody performance in immunohistochemistry?

While the EKI1 antibody described in the search results is primarily recommended for Western blot applications, researchers may want to explore its utility in immunohistochemistry (IHC). Based on best practices for antibody optimization in IHC, the following protocol recommendations can be considered:

• Tissue Processing and Antigen Retrieval:

  • Fix tissues in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin following standard protocols

  • Section tissues at 3-5 μm thickness

  • Test multiple antigen retrieval methods:
    a) Heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0)
    b) HIER with EDTA buffer (pH 9.0)
    c) Enzymatic retrieval with proteinase K

• Antibody Titration:

  • Begin with a concentration range (1:100 to 1:1000)

  • Assess staining intensity and specificity at each dilution

  • Select optimal dilution based on signal-to-noise ratio

• Detection System Selection:

  • Compare polymer-based detection systems similar to EnVision FLEX

  • Evaluate chromogen options (DAB vs. others) for optimal visualization

  • Consider amplification systems for low-abundance targets

• Validation Controls:

  • Include positive control tissues known to express ETNK1 (kidney, liver, placenta)

  • Use negative controls (primary antibody omission, non-expressing tissues)

  • Consider using multiple antibodies targeting different epitopes of ETNK1

Drawing from studies of other antibodies, optimization should aim for strong specific nuclear or cytoplasmic staining (depending on the cellular localization of ETNK1) with minimal background, similar to the performance standards established for antibodies like EP1 .

How can protein-protein interactions of ETNK1 be studied using EKI1 antibodies?

Protein-protein interactions (PPIs) of ETNK1 can be investigated using EKI1 antibodies through several techniques:

• Co-Immunoprecipitation (Co-IP):

  • Lyse cells in non-denaturing buffers to preserve protein-protein interactions

  • Use EKI1 antibody coupled to protein A/G beads to pull down ETNK1 and associated proteins

  • Analyze precipitated complexes by Western blot or mass spectrometry

  • Include appropriate controls: IgG control, input sample, and reverse Co-IP

• Proximity Ligation Assay (PLA):

  • Use EKI1 antibody in combination with antibodies against suspected interaction partners

  • Apply secondary antibodies with oligonucleotide probes

  • Visualize interactions as fluorescent spots when proteins are within 40nm proximity

  • Quantify signals to assess interaction strength

• Immunofluorescence Co-localization:

  • Perform dual immunofluorescence with EKI1 antibody and antibodies against potential partners

  • Analyze co-localization using confocal microscopy

  • Calculate Pearson's or Mander's coefficients to quantify co-localization

• Functional Validation:

  • Validate biological relevance of identified interactions through:
    a) Mutagenesis of interaction domains
    b) Competitive peptide inhibition
    c) Correlation with functional assays of phosphatidylethanolamine biosynthesis

Given ETNK1's function in phosphatidylethanolamine biosynthesis, potential interaction partners might include other enzymes in this pathway or regulatory proteins affecting ETNK1 activity .

What approaches can be used to quantify ETNK1 expression levels using EKI1 antibodies?

Accurate quantification of ETNK1 expression using EKI1 antibodies requires rigorous methodological approaches:

• Western Blot Quantification:

  • Use housekeeping proteins (β-actin, GAPDH) as loading controls

  • Employ standard curves with recombinant ETNK1 protein

  • Apply densitometry analysis with linear dynamic range verification

  • Normalize to total protein using stain-free technology or Ponceau S staining

• Immunohistochemistry Scoring Systems:

  • Develop a scoring system similar to those used for other proteins like ER:
    a) Percentage of positive cells (0-100%)
    b) Staining intensity (0-3+)
    c) H-score calculation (sum of %1+ × 1, %2+ × 2, %3+ × 3)

  • Employ digital image analysis for objective quantification

  • Correlate IHC scores with functional outcomes or clinical parameters

• Flow Cytometry:

  • Permeabilize cells appropriately for intracellular staining

  • Use directly labeled EKI1 antibodies or appropriate secondary antibodies

  • Include isotype controls and single-stained controls

  • Quantify Mean Fluorescence Intensity (MFI) relative to controls

• Correlation with mRNA Expression:

  • Similar to strategies used for other proteins, validate protein expression data by correlating with ETNK1 mRNA levels

  • Calculate correlation coefficients (e.g., Pearson's r) between protein and mRNA measurements

  • Address discrepancies through analysis of post-transcriptional regulation

This multi-modal approach to quantification enhances reliability and facilitates meaningful comparison across experimental conditions and studies.

How is ETNK1 implicated in disease pathology, and how can EKI1 antibodies advance this research?

ETNK1 has been implicated in several disease processes, and EKI1 antibodies serve as valuable tools for investigating these associations:

• Hematological Malignancies:

  • ETNK1 mutations have been identified in atypical chronic myeloid leukemia (aCML) and myelodysplastic/myeloproliferative neoplasms

  • EKI1 antibodies can be employed to:
    a) Evaluate ETNK1 protein expression in patient samples
    b) Assess the impact of disease-associated mutations on protein levels
    c) Study alterations in subcellular localization in diseased states

• Phospholipid Metabolism Disorders:

  • As ETNK1 functions in phosphatidylethanolamine biosynthesis, dysfunctions may contribute to membrane abnormalities

  • EKI1 antibodies enable:
    a) Quantification of ETNK1 levels in affected tissues
    b) Correlation of expression with phosphatidylethanolamine levels
    c) Examination of potential compensatory mechanisms

• Research Strategies:

  • Compare ETNK1 expression between normal and diseased tissues

  • Correlate expression patterns with disease progression and outcomes

  • Investigate potential therapeutic approaches targeting ETNK1 or its pathway

EKI1 antibodies provide essential tools for examining the role of ETNK1 in disease mechanisms, potentially leading to new diagnostic or therapeutic approaches .

What are the differential expression patterns of ETNK1 across tissue types, and how can this be studied?

Understanding ETNK1 expression patterns across different tissues provides valuable insights into its physiological roles. EKI1 antibodies facilitate comprehensive tissue expression profiling:

• Known Tissue Expression Profile:

  • ETNK1 is expressed in multiple tissues including kidney, liver, placenta, heart, leukocytes, ovary, and testis

  • This diverse expression pattern suggests broad physiological roles beyond tissue-specific functions

• Methodological Approaches for Expression Profiling:

  • Tissue Microarrays (TMAs):
    a) Construct TMAs containing multiple normal and diseased tissues
    b) Apply standardized IHC protocols with EKI1 antibodies
    c) Score expression patterns using consistent quantification methods

  • Multi-Organ Western Blot Analysis:
    a) Prepare protein extracts from different tissue types
    b) Perform Western blot with EKI1 antibody (1:1000 dilution)
    c) Normalize expression to appropriate housekeeping proteins
    d) Quantify relative expression levels across tissues

  • Correlation with Transcriptomic Data:
    a) Compare protein expression patterns with publicly available RNA-seq datasets
    b) Identify tissues with discordant mRNA and protein levels
    c) Investigate potential post-transcriptional regulatory mechanisms

• Functional Implications:

  • Relate tissue-specific expression patterns to phosphatidylethanolamine requirements

  • Investigate tissue-specific interactions or regulatory mechanisms

  • Examine potential roles in tissue-specific pathologies

This comprehensive mapping of ETNK1 expression contributes to our understanding of its physiological significance and potential involvement in tissue-specific disease processes.

How can EKI1 antibodies be applied in high-throughput screening and drug discovery research?

EKI1 antibodies offer significant potential for advancing high-throughput screening and drug discovery initiatives targeting the phosphatidylethanolamine synthesis pathway:

• Assay Development for Drug Screening:

  • Cell-Based Reporter Assays:
    a) Develop ETNK1 activity reporters linked to fluorescent readouts
    b) Use EKI1 antibodies to validate target engagement of screening hits
    c) Establish correlation between ETNK1 protein levels and enzymatic activity

  • High-Content Screening:
    a) Apply EKI1 antibodies for immunofluorescence-based screening
    b) Assess compounds that modulate ETNK1 expression, localization, or interactions
    c) Implement automated image analysis for quantification

• Target Validation Strategies:

  • Pharmacological Validation:
    a) Confirm compound effects on ETNK1 protein levels and phosphorylation status
    b) Assess downstream consequences on phosphatidylethanolamine biosynthesis
    c) Evaluate on-target vs. off-target effects through parallel approaches

  • Genetic Validation:
    a) Correlate EKI1 antibody staining with CRISPR/siRNA knockdown phenotypes
    b) Implement rescue experiments with wild-type or mutant ETNK1

• Biomarker Development:

  • Evaluate ETNK1 expression as a potential biomarker for disease stratification

  • Develop standardized immunoassays for clinical sample analysis

  • Correlate ETNK1 levels with response to therapeutic interventions

By leveraging EKI1 antibodies in these applications, researchers can accelerate the development of therapeutics targeting ETNK1 or its associated pathways.

What advanced analytical techniques can enhance the specificity and sensitivity of EKI1 antibody-based assays?

Implementing advanced analytical techniques can significantly improve the performance of EKI1 antibody-based assays:

• Multiplexed Detection Systems:

  • Mass Cytometry (CyTOF):
    a) Conjugate EKI1 antibodies with rare earth metals
    b) Simultaneously detect ETNK1 alongside dozens of other proteins
    c) Enable high-dimensional analysis of ETNK1 in complex cellular contexts

  • Multiplexed Immunofluorescence:
    a) Implement cyclic immunofluorescence or spectral unmixing
    b) Analyze ETNK1 in relation to multiple pathway components
    c) Preserve spatial information within tissue architecture

• Single-Cell Analysis:

  • Single-Cell Western Blot:
    a) Detect ETNK1 at single-cell resolution
    b) Assess heterogeneity in expression levels
    c) Correlate with phenotypic variations

  • Mass Spectrometry Immunoassays:
    a) Combine immunoprecipitation with targeted mass spectrometry
    b) Achieve high specificity through peptide-level identification
    c) Distinguish between ETNK1 variants or modified forms

• Signal Amplification Strategies:

  • Proximity Extension Assays:
    a) Couple oligonucleotide-conjugated antibodies with PCR amplification
    b) Achieve sub-picogram sensitivity for ETNK1 detection
    c) Enable quantification from minimal sample volumes

  • Tyramide Signal Amplification:
    a) Enhance IHC detection sensitivity through enzymatic signal amplification
    b) Enable detection of low-abundance ETNK1 expression
    c) Maintain spatial resolution in tissue contexts

These advanced techniques extend the utility of EKI1 antibodies beyond conventional applications, enabling more sensitive and informative analyses of ETNK1 biology.